AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3124456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate therapy
Number of subjects: 7
Study 3124456 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 30428548 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year empowerment-based health-promotion school intervention
Number of subjects: 135
Study 30428548 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 135
Study 27608264 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 3680
Study 27608264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 3680
Study 25068497 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7‐TT vaccine
Number of subjects: 0
Study 25068497 — intervention group
Group type: COMPARATOR
Intervention: Synflorix (control vaccine)
Number of subjects: 0
Study 22332211 — intervention group
Group type: COMPARATOR
Intervention: Sham injections plus prompt laser
Number of subjects: 423
Study 22332211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections plus prompt laser
Number of subjects: 423
Study 22332211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injections plus deferred laser
Number of subjects: 423
Study 22332211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injections plus prompt laser
Number of subjects: 423
Study 22332211 — intervention group
Group type: COMPARATOR
Intervention: Sham injections plus prompt laser (for participants with 2 study eyes)
Number of subjects: 423
Study 20387250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 160
Study 20387250 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 160
Study 18508948 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg oral dose of deferasirox tablets
Number of subjects: 17
Study 18508948 — intervention group
Group type: COMPARATOR
Intervention: 130 mg intravenous infusion of deferasirox
Number of subjects: 17
Study 16001345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic contrast agent SHU 508A
Number of subjects: 18
Study 16001345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16001345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic subjects
Number of subjects: 18
Study 16001345 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 18
Study 12492738 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (group 4 treatment) for duodenal ulcer patients
Number of subjects: 2751
Study 12492738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day treatment
Number of subjects: 2751
Study 12492738 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 treatment
Number of subjects: 2751
Study 12492738 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 60
Number of subjects: 2751
Study 12492738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance
Number of subjects: 2751
Study 10805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 12
Study 10805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan + Isosorbide-5-mononitrate
Number of subjects: 12
Study 10805056 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 12
Study 10805056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8723453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg dose, orally and intravenously)
Number of subjects: 30
Study 1900148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin C (MMC), 20 mg/m2 administered intravenously once every 6 weeks for four consecutive cycles
Number of subjects: 70
Study 1900148 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no further treatment after surgery
Number of subjects: 70
Study 6394640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of oestradiol percutaneously
Number of subjects: 43
Study 6394640 — intervention group
Group type: COMPARATOR
Intervention: 2 mg of oestradiol orally
Number of subjects: 43
Study 29986607 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending
Number of subjects: 0
Study 29986607 — intervention group
Group type: COMPARATOR
Intervention: Art therapy
Number of subjects: 0
Study 29394148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT) at FI02 = 10.6-11.4%
Number of subjects: 15
Study 29394148 — intervention group
Group type: COMPARATOR
Intervention: Normoxic group (NG) exercising at ambient air
Number of subjects: 15
Study 29394148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 15
Study 29394148 — intervention group
Group type: COMPARATOR
Intervention: Normoxic group (NG)
Number of subjects: 15
Study 29394148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT) and Normoxic group (NG)
Number of subjects: 15
Study 27302510 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy (CR)
Number of subjects: 108
Study 27302510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated tomotherapy (TT)
Number of subjects: 108
Study 1358483 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (discontinued treatment when serum TSH level and TBII activity normalized)
Number of subjects: 163
Study 1358483 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (treated for 24 months irrespective of serum TSH level and TBII activity)
Number of subjects: 163
Study 1358483 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 163
Study 1358483 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 163
Study 1358483 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and laboratory parameters
Number of subjects: 163
Study 20589566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 20589566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0
Study 20589566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and CBT
Number of subjects: 0
Study 20589566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18331130 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 0
Study 15818102 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole suspension (40 mg doses on day 1, then 40 mg daily for up to 14 days)
Number of subjects: 359
Study 15818102 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (300 mg bolus and 50 mg/hr for up to 14 days)
Number of subjects: 359
Study 15818102 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole suspension
Number of subjects: 359
Study 15818102 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 359
Study 12201080 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP Modulite (1000 micrograms twice-daily)
Number of subjects: 0
Study 12201080 — intervention group
Group type: COMPARATOR
Intervention: BDP-CFC (Becloforte)
Number of subjects: 0
Study 12201080 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafine BDP-HFA (QVAR)
Number of subjects: 0
Study 12201080 — intervention group
Group type: COMPARATOR
Intervention: CFC products
Number of subjects: 0
Study 10495335 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant output nebulization (5 min)
Number of subjects: 165
Study 10495335 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-synchronized nebulization (5 min)
Number of subjects: 165
Study 8758093 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 2mg/kg on days 1, 2, 3, 4, 5, 6, and 10 (total dose 14 mg/kg)
Number of subjects: 30
Study 8758093 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 2 mg/kg on days 1, 2, 3, 4, and 10 (total dose 10 mg/kg)
Number of subjects: 30
Study 8758093 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome 2 mg/kg on days 1, 5 and 10 (total dose 6 mg/kg)
Number of subjects: 30
Study 8758093 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 1753719 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg caffeine
Number of subjects: 36
Study 1753719 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 36
Study 1753719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 36
Study 3830953 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction (RY)
Number of subjects: 22
Study 3830953 — intervention group
Group type: COMPARATOR
Intervention: Longmire-Mouchet reconstruction (LM)
Number of subjects: 22
Study 30882527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aerobic training by cycle ergometer
Number of subjects: 37
Study 30882527 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (including occupational therapy)
Number of subjects: 37
Study 29801156 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐Con training
Number of subjects: 465
Study 29801156 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional flashcards
Number of subjects: 465
Study 29801156 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio kits with embedded flashcards
Number of subjects: 465
Study 29801156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 465
Study 27855428 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided square dance exercise 60‐90 min at least 5 times per week for 3 months
Number of subjects: 50
Study 27855428 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study 25199619 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Number of subjects: 40
Study 25199619 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 40
Study 22361318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (Ozurdex)
Number of subjects: 690
Study 20554790 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg Ca/d)
Number of subjects: 125
Study 20554790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 21864399 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment intervention by a specialist physician in geriatric medicine
Number of subjects: 400
Study 21864399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 16060203 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medicine (individually prescribed) for 6 weeks
Number of subjects: 28
Study 16060203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar granules) for 6 weeks
Number of subjects: 28
Study 16060203 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medicine (individually prescribed) during open follow-up
Number of subjects: 28
Study 16060203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar granules) during open follow-up
Number of subjects: 28
Study 16060203 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medicine
Number of subjects: 28
Study 16060203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12361129 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% erythromycin gel
Number of subjects: 208
Study 12361129 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 208
Study 9832293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg x ml(‐1) oxymetazoline (Group B)
Number of subjects: 36
Study 9832293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x ml(‐1) oxymetazoline (Group C)
Number of subjects: 36
Study 9832293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 36
Study 8018452 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lofepramine (70 mg once daily)
Number of subjects: 63
Study 8018452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2919736 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperitonealization of the gallbladder bed
Number of subjects: 88
Study 2919736 — intervention group
Group type: COMPARATOR
Intervention: Raw surface left uncovered (Control)
Number of subjects: 88
Study 29235884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 344
Study 29235884 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (60 mg/day)
Number of subjects: 344
Study 29235884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day) with UPSA score change ≥9
Number of subjects: 344
Study 29235884 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (60 mg/day) with UPSA score change ≥9
Number of subjects: 344
Study 29081922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Number of subjects: 0
Study 29081922 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 29081922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26436422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetranychus cinnabarinus (Boisd.) protonymphs
Number of subjects: 0
Study 26436422 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemisia tabaci (Gennadius) eggs
Number of subjects: 0
Study 26436422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of T. cinnabarinus protonymphs and B. Tabaci eggs
Number of subjects: 0
Study 26436422 — intervention group
Group type: COMPARATOR
Intervention: B. Tabaci eggs
Number of subjects: 0
Study 26436422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of both prey
Number of subjects: 0
Study 26436422 — intervention group
Group type: EXPERIMENTAL
Intervention: T. cinnabarinus
Number of subjects: 0
Study 24219579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention for lowering uric acid (education package)
Number of subjects: 19724
Study 24219579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19724
Study 20936577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic examination training by a gynecological teaching associate (GTA) alone
Number of subjects: 106
Study 20936577 — intervention group
Group type: COMPARATOR
Intervention: Pelvic examination training by a standardized patient (SP) with an obstetrics and gynecology faculty member
Number of subjects: 106
Study 18634549 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative physiotherapy
Number of subjects: 184
Study 18634549 — intervention group
Group type: COMPARATOR
Intervention: Standard care nursing and medical interventions (Control Group)
Number of subjects: 184
Study 16782312 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (95% were selective serotonin or norepinephrine reuptake inhibitors, or second-generation antidepressants)
Number of subjects: 182
Study 16782312 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (with concurrent mood stabilizer)
Number of subjects: 182
Study 16782312 — intervention group
Group type: COMPARATOR
Intervention: Usual care without antidepressants
Number of subjects: 182
Study 14504184 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 8 weeks
Number of subjects: 50
Study 14504184 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg daily for 8 weeks
Number of subjects: 50
Study 11099761 — intervention group
Group type: EXPERIMENTAL
Intervention: Executed actions with varying target force (low, moderate) and rate of force development (slow, rapid)
Number of subjects: 0
Study 11099761 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined actions with varying target force (low, moderate) and rate of force development (slow, rapid)
Number of subjects: 0
Study 11099761 — intervention group
Group type: EXPERIMENTAL
Intervention: Executed actions at SMA/PMA with varying target force (low, moderate)
Number of subjects: 0
Study 11099761 — intervention group
Group type: EXPERIMENTAL
Intervention: Executed actions at FCz with varying rate of force development (rapid, slow)
Number of subjects: 0
Study 8805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin in combination with teniposide and vincristine
Number of subjects: 484
Study 8805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin in combination with teniposide and vincristine
Number of subjects: 484
Study 8805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with teniposide plus cisplatin or carboplatin
Number of subjects: 484
Study 8805928 — intervention group
Group type: COMPARATOR
Intervention: Alternating treatment with block A, B and C (arm III)
Number of subjects: 484
Study 1458770 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min for 15 minutes)
Number of subjects: 10
Study 1458770 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 10
Study 6385890 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg every 6 hours)
Number of subjects: 50
Study 6385890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31613885 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured model for integrated OA care (SAMBA model) facilitated by workshops and physiotherapist-led education and exercise programme for 8-12 weeks.
Number of subjects: 393
Study 31613885 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured model for integrated OA care (SAMBA model)
Number of subjects: 393
Study 31613885 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 393
Study 29051047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy Self-management Training (OSMT) program delivered via telehealth; includes four group sessions and an additional session for caregivers.
Number of subjects: 0
Study 27015578 — intervention group
Group type: EXPERIMENTAL
Intervention: LMAP (target MAP of 50 mm Hg)
Number of subjects: 168
Study 27015578 — intervention group
Group type: COMPARATOR
Intervention: HMAP (target MAP of 65 mm Hg)
Number of subjects: 168
Study 24662864 — intervention group
Group type: EXPERIMENTAL
Intervention: HSA plus high FFP/RBC resuscitation (Group D)
Number of subjects: 94
Study 24662864 — intervention group
Group type: COMPARATOR
Intervention: Balanced electrolyte solution (BES) plus low FFP/RBC resuscitation (Group A)
Number of subjects: 94
Study 23087138 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BNP) 0.000025 g x kg(‐2) administered by patient‐controlled intravenous analgesia (PCIA)
Number of subjects: 120
Study 23087138 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.00075 g x kg(‐2)
Number of subjects: 120
Study 23087138 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.0011 g x kg(‐2)
Number of subjects: 120
Study 21053703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement and cessation counseling
Number of subjects: 755
Study 21053703 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 755
Study 18843002 — intervention group
Group type: EXPERIMENTAL
Intervention: BR-DIM 100 mg
Number of subjects: 4
Study 18843002 — intervention group
Group type: EXPERIMENTAL
Intervention: BR-DIM 200 mg
Number of subjects: 4
Study 18843002 — intervention group
Group type: EXPERIMENTAL
Intervention: BR-DIM 300 mg
Number of subjects: 4
Study 18843002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 16086621 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 328
Study 16086621 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 328
Study 12036805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterol-free corn oil
Number of subjects: 10
Study 12036805 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil with 150 mg phytosterols
Number of subjects: 10
Study 12036805 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil with 300 mg phytosterols
Number of subjects: 10
Study 12036805 — intervention group
Group type: COMPARATOR
Intervention: Commercial corn oil
Number of subjects: 10
Study 9461319 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentrations in lean women (BMI <25 kg/m2)
Number of subjects: 415
Study 9461319 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentrations in lean men (BMI <25 kg/m2)
Number of subjects: 415
Study 9461319 — intervention group
Group type: COMPARATOR
Intervention: Leptin concentrations in moderately overweight and obese individuals (BMI 25-30 kg/m2 and BMI >30 kg/m2)
Number of subjects: 415
Study 8569975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxyvitamin D3 derivatives
Number of subjects: 0
Study 8569975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of alkaline salts of calcium
Number of subjects: 0
Study 8569975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dialysate calcium concentrations (1.25-1.00 mmol/l)
Number of subjects: 0
Study 8569975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhypercalcemic hyperphosphatemic vitamin D3 derivatives in combination with oral calcium
Number of subjects: 0
Study 8569975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D derivatives
Number of subjects: 0
Study 1697390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 14
Study 1697390 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 14
Study 1697390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nisoldipine and propranolol
Number of subjects: 14
Study 1697390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1697390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 14
Study 1697390 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study 100331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast interferon preparations for 3 months
Number of subjects: 0
Study 100331 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31881599 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroForm device
Number of subjects: 50